A combined computational and experimental approach to the evolution and role of the DNA sequence environment in targeting mutations to antibody V regions
一种结合计算和实验的方法来研究 DNA 序列环境的进化和在抗体 V 区靶向突变中的作用
基本信息
- 批准号:10375356
- 负责人:
- 金额:$ 57.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-03-01 至 2024-02-29
- 项目状态:已结题
- 来源:
- 关键词:AffectAllelesAnimal ExperimentsAntibodiesAntibody AffinityAntigensAutoimmunityB lymphoid malignancyB-Cell DevelopmentB-Cell LymphomasB-LymphocytesBiologicalBiologyCell LineChromatinComplementarity Determining RegionsComputer AnalysisComputer ModelsDNADNA SequenceDataDatabasesDevelopmentDiseaseEnvironmentEnzyme ActivationEvaluationEventEvolutionFamilyFeedbackFrequenciesFutureGTP-Binding Protein alpha Subunits, GsGene-ModifiedGenesGoalsHIVHeavy-Chain ImmunoglobulinsHumanHuman Cell LineImmune responseImmunityImmunoglobulin Somatic HypermutationImmunoglobulinsIndividualInfectionInfectious AgentInfluenzaInfluenza HemagglutininKnock-inLeadLocationMachine LearningMalignant NeoplasmsMediatingMedicalMismatch RepairMolecularMusMutateMutationOutcomePatternPlayPolymeraseProcessPublic HealthResearchRisk FactorsRoleSiteSolid NeoplasmStatistical ModelsStomachStructure of germinal center of lymph nodeTechniquesTestingTherapeutic antibodiesTimeTransgenic MiceValidationVariantactivation-induced cytidine deaminasebasechromatin modificationdensityexperimental studygenetic varianthuman datain vivoin vivo Modelinnovationneutralizing antibodyrecruitrepair enzymeresponsespatial relationshipvaccine developmentvaccine responsevaccine-induced antibodies
项目摘要
Project summary
There is a fundamental gap in our understanding of how mutations are preferentially targeted to the variable
(V) regions of the Immunoglobulin (Ig) loci during somatic hypermutation (SHM). The persistence of this gap
has limited our understanding of the mutagenic mechanisms involving activation-induced deaminase (AID)
in the immune response and in the role of AID in mis-targeting mutations leading to B-cell lymphomas and
other cancers. The long-term goal of the proposed research is to understand the global targeting of
mutations in immunity that are required to protect us from infections. As high-throughput data from human
antibody immune responses became available, it provided us with new opportunities to generate
hypotheses to explain the underlying mechanisms of SHM. We now propose to generate further hypotheses
using computational models applied to additional databases and to validate these hypotheses using cellular
and animal experiments. Our objective is to understand what directs SHM across the many human Ig heavy
chain V-regions. Our central hypothesis is that the V-region SHM process is highly dependent on a DNA
sequence signature(s) that drives mutations in a largely deterministic fashion. This hypothesis is supported
by our preliminary results using human in vivo data from a few human V region genes and has begun to be
validated using independent databases and experiments in human B cell lines. The rationale is that
evaluations of computational data based upon biological mechanisms, together with appropriate biological
experiments, will reveal the key differences between IGHV regions (IGHV 3-23, 4-34, 1-18, 1-02, etc.) that
lead to the dominance of each of those V regions in the responses to medically important antigens. Our
hypothesis will be tested by pursuing two specific aims: 1) identify the extent to which a DNA signature
determines the mutation process in four individual human IGHV genes that are important in disease
responses; 2) examine the relationship between AID hotspots and Polη hotspots across all the other human
V region genes, thus rigorously defining a mutation targeting signature. Both aims will also entail studying
human V region genes and modifications of them in human cell lines and in mice expressing a human V
region to further confirm the signature and identify molecular mechanisms in vivo. Our approach is
innovative because the computational models we are proposing will be mechanistically motivated focusing
on the interaction between AID and Polη hotspots, thus testing molecular mechanisms as opposed to
classic statistical models using whole V region sequences that ignore the underlying biology. In addition, to
focus on mechanisms we will leverage new high-throughput data from human V regions that have not
undergone antigen selection. Our results will be highly relevant to human IgV repertoire analyses from
immune responses that are currently hard to interpret and will help future vaccine and therapeutic antibody
development, as well as help to understand mutations in human malignancies where AID plays a key role.
项目概要
我们对突变如何优先针对变量的理解存在根本差距
(V) 体细胞超突变 (SHM) 期间免疫球蛋白 (Ig) 基因座的区域。这种差距的持续存在
限制了我们对涉及激活诱导脱氨酶(AID)的诱变机制的理解
免疫反应以及 AID 在导致 B 细胞淋巴瘤的错误靶向突变中的作用
其他癌症。拟议研究的长期目标是了解全球目标
保护我们免受感染所需的免疫突变。作为来自人类的高通量数据
抗体免疫反应的出现,为我们提供了产生新的机会
解释 SHM 潜在机制的假设。我们现在建议产生进一步的假设
使用应用于其他数据库的计算模型并使用细胞验证这些假设
和动物实验。我们的目标是了解是什么引导 SHM 跨越许多人类 Ig 重链
链V区。我们的中心假设是 V 区 SHM 过程高度依赖于 DNA
以很大程度上确定性的方式驱动突变的序列签名。这个假设得到支持
根据我们的初步结果,使用来自一些人类 V 区基因的人体数据,并已开始
使用独立数据库和人类 B 细胞系实验进行验证。理由是
基于生物机制的计算数据的评估,以及适当的生物
实验,将揭示 IGHV 区域(IGHV 3-23、4-34、1-18、1-02 等)之间的关键差异,
导致每个 V 区在对医学上重要抗原的反应中占主导地位。我们的
假设将通过追求两个具体目标来检验:1)确定 DNA 特征的程度
确定四个对疾病很重要的人类 IGHV 基因的突变过程
回应; 2)检查所有其他人类的 AID 热点和 Polη 热点之间的关系
V 区基因,从而严格定义突变靶向特征。这两个目标还需要学习
人类V区基因及其在人类细胞系和表达人类V区的小鼠中的修饰
区域以进一步确认特征并确定体内分子机制。我们的方法是
创新,因为我们提出的计算模型将是机械驱动的聚焦
关于 AID 和 Polη 热点之间的相互作用,从而测试分子机制,而不是
使用整个 V 区序列的经典统计模型忽略了潜在的生物学。此外
重点关注我们将利用来自人类 V 区的新高通量数据的机制,这些数据尚未
经过抗原选择。我们的结果将与人类 IgV 库分析高度相关
目前难以解释的免疫反应将有助于未来的疫苗和治疗性抗体
发展,并有助于了解 AID 在人类恶性肿瘤中发挥关键作用的突变。
项目成果
期刊论文数量(16)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Mutational pressure by host APOBEC3s more strongly affects genes expressed early in the lytic phase of herpes simplex virus-1 (HSV-1) and human polyomavirus (HPyV) infection.
宿主 APOBEC3 的突变压力更强烈地影响单纯疱疹病毒 1 (HSV-1) 和人多瘤病毒 (HPyV) 感染裂解期早期表达的基因。
- DOI:10.1371/journal.ppat.1009560
- 发表时间:2021-04
- 期刊:
- 影响因子:6.7
- 作者:Shapiro M;Krug LT;MacCarthy T
- 通讯作者:MacCarthy T
AID Overlapping and Polη Hotspots Are Key Features of Evolutionary Variation Within the Human Antibody Heavy Chain (IGHV) Genes.
AID 重叠和 PolÎ 热点是人类抗体重链 (IGHV) 基因内进化变异的关键特征。
- DOI:10.3389/fimmu.2020.00788
- 发表时间:2020
- 期刊:
- 影响因子:7.3
- 作者:Tang,Catherine;Bagnara,Davide;Chiorazzi,Nicholas;Scharff,MatthewD;MacCarthy,Thomas
- 通讯作者:MacCarthy,Thomas
STAT3 imparts BRCAness by impairing homologous recombination repair in Epstein-Barr virus-transformed B lymphocytes.
STAT3 通过损害 Epstein-Barr 病毒转化的 B 淋巴细胞的同源重组修复来赋予 BRCAness。
- DOI:10.1371/journal.ppat.1008849
- 发表时间:2020-10
- 期刊:
- 影响因子:6.7
- 作者:McIntosh MT;Koganti S;Boatwright JL;Li X;Spadaro SV;Brantly AC;Ayers JB;Perez RD;Burton EM;Burgula S;MacCarthy T;Bhaduri-McIntosh S
- 通讯作者:Bhaduri-McIntosh S
The cytidine deaminase under-representation reporter (CDUR) as a tool to study evolution of sequences under deaminase mutational pressure.
- DOI:10.1186/s12859-018-2161-y
- 发表时间:2018-05-02
- 期刊:
- 影响因子:3
- 作者:Shapiro M;Meier S;MacCarthy T
- 通讯作者:MacCarthy T
Post-Transformation IGHV-IGHD-IGHJ Mutations in Chronic Lymphocytic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course.
- DOI:10.3389/fonc.2021.640731
- 发表时间:2021
- 期刊:
- 影响因子:4.7
- 作者:Bagnara D;Tang C;Brown JR;Kasar S;Fernandes S;Colombo M;Vergani S;Mazzarello AN;Ghiotto F;Bruno S;Morabito F;Rai KR;Kolitz JE;Barrientos JC;Allen SL;Fais F;Scharff MD;MacCarthy T;Chiorazzi N
- 通讯作者:Chiorazzi N
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERT C. RIZZO其他文献
ROBERT C. RIZZO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERT C. RIZZO', 18)}}的其他基金
Development, Validation, and Application of Structure-based Tools for Computational Molecular Design
基于结构的计算分子设计工具的开发、验证和应用
- 批准号:
10455100 - 财政年份:2018
- 资助金额:
$ 57.88万 - 项目类别:
Development, Validation, and Application of Structure-based Tools for Computational Molecular Design
基于结构的计算分子设计工具的开发、验证和应用
- 批准号:
10226099 - 财政年份:2018
- 资助金额:
$ 57.88万 - 项目类别:
Computational Design of Fusion Inhibitors Targeting Drug-resistant HIVgp41
针对耐药 HIVgp41 的融合抑制剂的计算设计
- 批准号:
8247014 - 财政年份:2008
- 资助金额:
$ 57.88万 - 项目类别:
Computational Design of Fusion Inhibitors Targeting Drug-resistant HIVgp41
针对耐药 HIVgp41 的融合抑制剂的计算设计
- 批准号:
8055893 - 财政年份:2008
- 资助金额:
$ 57.88万 - 项目类别:
Computational Design of Fusion Inhibitors Targeting Drug-resistant HIVgp41
针对耐药 HIVgp41 的融合抑制剂的计算设计
- 批准号:
7597119 - 财政年份:2008
- 资助金额:
$ 57.88万 - 项目类别:
Computational Design of Fusion Inhibitors Targeting Drug-resistant HIVgp41
针对耐药 HIVgp41 的融合抑制剂的计算设计
- 批准号:
8467315 - 财政年份:2008
- 资助金额:
$ 57.88万 - 项目类别:
Computational Design of Fusion Inhibitors Targeting Drug-resistant HIVgp41
针对耐药 HIVgp41 的融合抑制剂的计算设计
- 批准号:
7797534 - 财政年份:2008
- 资助金额:
$ 57.88万 - 项目类别:
Computational Design of Fusion Inhibitors Targeting Drug-resistant HIVgp41
针对耐药 HIVgp41 的融合抑制剂的计算设计
- 批准号:
7495418 - 财政年份:2008
- 资助金额:
$ 57.88万 - 项目类别:
Computational Design of Fusion Inhibitors Targeting Drug-resistant HIVgp41
针对耐药 HIVgp41 的融合抑制剂的计算设计
- 批准号:
8720786 - 财政年份:2008
- 资助金额:
$ 57.88万 - 项目类别:
Computational Design of Fusion Inhibitors Targeting Drug-resistant HIVgp41
针对耐药 HIVgp41 的融合抑制剂的计算设计
- 批准号:
8915303 - 财政年份:2008
- 资助金额:
$ 57.88万 - 项目类别:
相似海外基金
Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
- 批准号:
502556 - 财政年份:2024
- 资助金额:
$ 57.88万 - 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
- 批准号:
10659303 - 财政年份:2023
- 资助金额:
$ 57.88万 - 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
$ 57.88万 - 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
- 批准号:
10758772 - 财政年份:2023
- 资助金额:
$ 57.88万 - 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
- 批准号:
10676499 - 财政年份:2023
- 资助金额:
$ 57.88万 - 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
- 批准号:
2748611 - 财政年份:2022
- 资助金额:
$ 57.88万 - 项目类别:
Studentship
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
- 批准号:
22K05630 - 财政年份:2022
- 资助金额:
$ 57.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
- 批准号:
10532032 - 财政年份:2022
- 资助金额:
$ 57.88万 - 项目类别:
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
- 批准号:
10525070 - 财政年份:2022
- 资助金额:
$ 57.88万 - 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
- 批准号:
10689017 - 财政年份:2022
- 资助金额:
$ 57.88万 - 项目类别:














{{item.name}}会员




